Scientific Advisory
The Prima BioMed Scientific Advisory Board (SAB) provides independent scientific review of Prima BioMed´s product development programs and new product opportunities. The Scientific Advisory Board members are eminent scientists and technologists with relevant commercial and business exposure in the biotechnology and pharmaceutical sectors.
Scientific Advisory Board consists of
• Prof Ian Frazer (Chair), UQ Diamantina Cancer Centre
• Dr Michelle Vaughan, Christchurch Hospital Oncology
• Dr Heidi Gray, Fred Hutchinson Cancer Centre
• Prof Bruce Loveland, Austin Cancer Research
• Dr Joyce Frey-Vasconcelles, Former US FDA Director
The role of the SAB is to:
• assess the scientific credibility of research proposals
• regularly review progress of funded programs
• provide critical scientific review of proposed development strategies
• provide advice on the appropriateness of research costs
• advise on the probability of the development team achieving proposed outcomes.
Prima establishes Technical Review committees for each investment program that provide reports that the Board of Directors use to monitor progress of investments. A member of the SAB sits on each committee.
Prima has also established a Clinical Advisory Board to provide guidance for new and existing clinical programs. The board also reviews new opportunities for in-licensing for the company.
The board is chaired by Dr Jonathan Berek of Stanford University.
|
|